Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 8;4(3):e395.
doi: 10.1097/HS9.0000000000000395. eCollection 2020 Jun.

Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study

Affiliations

Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study

Andrea Visentin et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Descriptive graphs and survival curves. (A) The upper left panel shows the apple-pie graph of WNV infection; 71% of patients had a WNVND, while 29% did not have a documented spread to central nervous system. (B) The upper right panel reports a scatter plot of serum IgG, IgA, and IgM immunoglobulin levels in patients with (n = 15) and without WNVND (n = 6). Immunoglobulins were measured once for each patient within 30 days before WNV infection. Cases with WNVND had significantly lower immunoglobulin levels as assessed by Mann-Whiteney U test. the lower panels report the overall survival of the whole cohort (C) and the WNV-related survival in patients with and without WNVND (D). Patients with WNVND have a short WNV-related survival (P = 0.0463). WNV = West Nile virus, WNVND = West Nile virus neuroinvasive disease.

References

    1. Visentin A, Imbergamo S, Gurrieri C, et al. Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. Eur J Cancer. 2017;72:103–111. - PubMed
    1. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–581. - PubMed
    1. Maffei R, Maccaferri M, Arletti L, et al. Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections. Blood Rev. 2020;40:100635. - PubMed
    1. Visentin A, Compagno N, Cinetto F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100:e515–e518. - PMC - PubMed
    1. Visentin A, Gurrieri C, Imbergamo S, et al. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematol Oncol. 2017;35:925–928. - PubMed